Biofarm S.A. manufactures pharmaceutical products. The company's products include cardiovascular, digestive and metabolic, genito-urinary, ophthalmological, endocrine, nervous system, osteo-muscular, respiratory and ENT, multivitamin, antiallergen, and dermatological products. Biofarm S.A. was founded in 1921 and is based in Bucharest, Romania. As of June 24, 2026, Biofarm S.A. operates as a subsidiary of Polpharma SA Pharmaceutical Works.…
Fapte dintr-un unrelated event: BIOFARM S.A. modifică calendarul financiar 2026
Biofarm (BVB: BIO) is listed on Bucharest Stock Exchange, where its shares trade in RON. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 374 employees.
The shares were at 1.370 RON on 19 November 2026, up 75.9% over 52 weeks. Its 52-week range is 0.7820 RON to 1.495 RON: the price is 8.4% below the high and 75.2% above the low.
At a market capitalisation of 1.35B RON, it trades at 19.6 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a discount of 20% for BIO. It pays a dividend yielding 3.07% (it pays out 105% of its earnings), against a median of 1.95% among the dividend payers in that peer group.
Biofarm reports return on equity of 18.4%, an operating margin of 23.2% and revenue down 33.2% year over year.
It holds more cash than debt, a net cash position of 206.88M RON. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.